IRB #

STUDY00021194

Title

A phase 1 study of SGN-CD228A in select advanced solid tumors

Principal Investigator

Shivaani Kummar

Study Purpose

This trial will study the study drug, SGN-CD228A, to find out whether it is an effective way to treat different kinds of cancer. The study will also look at what side effects (unwanted effects) may occur.

Medical Condition(s)

Cutaneous Melanoma
Pleural Mesothelioma
Breast Cancer
Non-small Cell Lung Cancer
Colorectal Cancer
Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

1. Individuals 18 years or older
2. Adequate organ function
3. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

The length of your participation in this study will depend on how long you receive the study drug. This could range from 1 day to more than 24 months. In this study we may continue to follow you indefinitely through telephone calls, medical record review, and/or clinic visits after you have received the last dose of the study drug(s).

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Seagen

Recruitment End

01/31/2023

Compensation Provided

No


Go Back